Monday, September 20

fármacos

ensayo clínico, farmaceutica, fármacos, Moderna, Noticias, pacientes, Salud, vacuna, vacunas, vih

Moderna begins trials of its HIV vaccine | Digital Trends Spanish

The pharmaceutical company Moderna reported that a phase I clinical trial of its HIV vaccine candidate will begin this week. For this you will use the same mRNA method that you used in your COVID-19 vaccine. According to the pharmaceutical company, this trial will serve to test the safety of the vaccine, in addition to measuring the immune response generated in a small group of healthy volunteers. In April, Moderna had announced its plans to develop an HIV vaccine, in conjunction with the International AIDS Vaccine Initiative and the Bill and Melinda Gates Foundation. The company's idea is to test two potential candidates, called mRNA-1644 and mRNA-1574. The trial will begin on August 19 and will involve 56 people who have not yet contracted HIV. How does it work? Messenger RNA vaccine...
Abdala, Covid 19, Cuba, fármacos, Noticias, Salud, SARS-CoV-2, vacuna, vacunas

Abdala: Cuba’s anti-COVID-19 vaccine with 92% efficacy | Digital Trends Spanish

According to BioCubaFarma, the anti-COVID-19 vaccine developed by Cuba would have an efficacy of more than 92.28 percent. According to the laboratory that produced the antigen, it would be close to becoming the first immunizer against the coronavirus created in Latin America. In its social networks, the Island's Center for Genetic Engineering and Biotechnology (CIGB) pointed out that with three doses the patient would obtain more than 90 percent protection against the coronavirus. 💉 Vaccine candidate #Abdala of @CIGBCuba shows an efficacy of 92.28% in its 3-dose scheme, reports @BioCubaFarma. In video, details on how this formulation is produced: https://t.co/RQv79UUgsk pic.twitter.com/zB7LCpSQrk & mdash; Scientific Observatory (@ObservaCiencia) June 22, 2021 Abdala is one of the fiv...